Although acute promyelocytic leukemia (APL) is one of the most characterized forms of
acute myeloid leukemia (AML), the molecular mechanisms involved in the development and …

This review highlights new findings that have deepened our understanding of the
mechanisms of leukemogenesis, therapy and resistance in acute promyelocytic leukemia …

Targeted therapy for acute myeloid leukemia (AML) is an effective strategy, but currently
there are very limited therapeutic targets for AML treatment. Histone lysine specific …

Acute myeloid leukemia (AML) is a genetically heterogeneous clonal malignancy
characterized by recurrent gene mutations. Genomic heterogeneity, patients' individual …

A cancer tumour consists of thousands of genetic mutations. Even after advancement in
technology, the task of distinguishing genetic mutations, which act as driver for the growth of …

Most acute promyelocytic leukemia (APL) are caused by PML-RARA, a translocation-driven
fusion oncoprotein discovered three decades ago. Over the years, several other types of …

Purpose: The current stratification system for acute promyelocytic leukemia (APL) is based
on the white blood cell (WBC) and the platelet counts (ie, Sanz score) over the past two …

Great efforts have been made to develop precision medicine-based treatments using
machine learning. In this field, where the goal is to provide the optimal treatment for each …

Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy with
complex heterogenous genetic and biological nature. Thus, prognostic prediction and …

The introduction of all-trans retinoic acid combined with anthracyclines has significantly
improved the outcomes for patients diagnosed with acute promyelocytic leukemia (APL) …